When technological discontinuities and disruptive business models challenge dominant industry logics: insights from the drugs industry

An industry's dominant logic is the general scheme of value creation and capture shared by its actors. In high technology fields, technological discontinuities are not enough to disrupt an industry's dominant logic. Identifying the factors that might trigger change in that logic can help companies develop strategies to enable them to capture greater value from their innovations by disrupting that logic. Based on analyzing the changes that biotechnologies and bioinformatics have brought to the drug industry, we identify and characterize three triggers of change that can create disruptive business models. We suggest that, in mature industries experiencing strong discontinuities and high technological uncertainty, entrants' business models initially tend to fit into the industry's established dominant logic and its value chains remain unchanged. But as new technologies evolve and uncertainty decreases, disruptive business models emerge, challenging dominant industry logics and reshaping established value chains.

[1]  George Wright,et al.  Confronting Strategic Inertia in a Top Management Team: Learning from Failure , 2002 .

[2]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[3]  Constance E. Helfat,et al.  Organizational Linkages for Surviving Technological Change: Complementary Assets, Middle Management, and Ambidexterity , 2008, Organ. Sci..

[4]  M. Tushman,et al.  On the Organizational Determinants of Technological Change: Towards a Sociology of Technological Evolution , 1992 .

[5]  Robert Phaal,et al.  A framework for mapping industrial emergence , 2011 .

[6]  C. Prahalad,et al.  The dominant logic: A new linkage between diversity and performance , 1986 .

[7]  James M. Utterback,et al.  Responding to Structural Industry Changes: A Technological Evolution Perspective , 1997 .

[8]  D. Light,et al.  Demythologizing the high costs of pharmaceutical research , 2011 .

[9]  C. Prahalad The Blinders of Dominant Logic , 2004 .

[10]  G. Krogh,et al.  Exploring the Link between Dominant Logic and Company Performance , 2000 .

[11]  D. Teece Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[12]  M. Storper The Regional World: Territorial Development in a Global Economy , 1997 .

[13]  M. Tushman,et al.  Technological Discontinuities and Dominant Designs: A Cyclical Model of Technological Change , 1990 .

[14]  Yu-Shan Su,et al.  Spontaneous vs. policy-driven: The origin and evolution of the biotechnology cluster , 2009 .

[15]  Ict Access,et al.  Working Party on the Information Economy , 2007 .

[16]  K. Marino,et al.  Developing consensus on firm competencies and capabilities , 1996 .

[17]  J. Leker,et al.  Anticipating converging industries using publicly available data , 2010 .

[18]  R. George Intellectual property and pharmaceutical drugs: an ethical analysis. , 2005 .

[19]  Mary J. Benner Securities Analysts and Incumbent Response to Radical Technological Change: Evidence from Digital Photography and Internet Telephony , 2010, Organ. Sci..

[20]  Kjell Grønhaug,et al.  Structure and Strategy in Grocery Retailing: A Sociometric Approach , 1985 .

[21]  Sidney G. Winter,et al.  Schumpeterian Competition in Alternative Technological Regimes , 1983 .

[22]  Andrew Lilico Six Issues in Pharmaceuticals , 2006 .

[23]  K. Pavitt Sectoral Patterns of Technical Change : Towards a Taxonomy and a Theory : Research Policy , 1984 .

[24]  K. Eisenhardt,et al.  Constructing Markets and Shaping Boundaries: Entrepreneurial Power in Nascent Fields , 2009 .

[25]  Mary J. Benner,et al.  Process Management and Technological Innovation: A Longitudinal Study of the Photography and Paint Industries , 2002 .

[26]  S. Klepper Industry Life Cycles , 1997 .

[27]  J. Reiss,et al.  The global health complex , 2011 .

[28]  J. Fisken,et al.  Business models and investment trends in the biotechnology industry in Europe , 2002 .

[29]  Gaurav Laroia,et al.  Managing Drug Discovery Alliances For Success , 2005 .

[30]  Robert K. Yin,et al.  Applications of case study research , 1993 .

[31]  V. Chiesa,et al.  Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis , 2011 .

[32]  Y. Doz,et al.  Embedding Strategic Agility A Leadership Agenda for Accelerating Business Model Renewal , 2010 .

[33]  Nikolaus Thumm,et al.  Strategic Patenting in Biotechnology , 2004, Technol. Anal. Strateg. Manag..

[34]  D. Bosse,et al.  Bargaining power in alliance governance negotiations: evidence from the biotechnology industry , 2010 .

[35]  J. Streim,et al.  America's other drug problem. , 1994, Provider.

[36]  G. Ginsburg,et al.  Personalized medicine: revolutionizing drug discovery and patient care. , 2001, Trends in biotechnology.

[37]  A. Arora,et al.  The changing technology of technological change: general and abstract knowledge and the division of , 1994 .

[38]  Vincent Mangematin,et al.  The future of drug discovery and development: Shifting emphasis towards personalized medicine , 2010 .

[39]  Christel Lane,et al.  The External Sourcing of Technological Knowledge by US Pharmaceutical Companies: Strategic Goals and Inter‐organizational Relationships , 2007 .

[40]  Michael H. Morris,et al.  The entrepreneur's business model: toward a unified perspective , 2005 .

[41]  Steven T. Walsh,et al.  Integrating Innovation and Learning Curve Theory: An Enabler for Moving Nanotechnologies and Other Emerging Process Technologies into Production , 2004 .

[42]  Friedrich Grosse-Dunker,et al.  Sustainability Innovation Cube - A Framework to Evaluate Sustainability-Oriented Innovations , 2009 .

[43]  Ursula Weisenfeld,et al.  Technology management and collaboration profile: virtual companies and industrial platforms in the high‐tech biotechnology industries , 2001 .

[44]  Barry L. Bayus,et al.  The Market Evolution and Sales Takeoff of Product Innovations , 2002, Manag. Sci..

[45]  Carine Staropoli Cooperation in R&D in the pharmaceutical industry — The network as an organizational innovation governing technological innovation , 1998 .

[46]  Xavier Lecocq,et al.  Business Model Evolution: In Search of Dynamic Consistency , 2010 .

[47]  M. Feldman Organizational Routines as a Source of Continuous Change , 2000 .

[48]  Charles W. L. Hill,et al.  Technological Discontinuities and Complementary Assets: A Longitudinal Study of Industry and Firm Performance , 2005, Organ. Sci..

[49]  Sabine Glesner,et al.  Editorial , 1864, Informatik - Forschung und Entwicklung.

[50]  James Mittra,et al.  Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms , 2007, Technol. Anal. Strateg. Manag..

[51]  C. K. Prahalad,et al.  THE DOMINANT LOGIC: RETROSPECTIVE AND EXTENSION , 1995 .

[52]  Harry Rothman,et al.  Downstream and into deep biology: Evolving business models in ‘top tier’ genomics companies , 2006 .

[53]  M. Sosna,et al.  Business Model Innovation through Trial-and-Error Learning , 2010 .

[54]  Vincent Mangematin,et al.  From Business model to Business model portfolio in the european biopharmaceutical industry , 2010 .

[55]  Oliver Gassmann,et al.  Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .

[56]  Ramon Casadesus-Masanell,et al.  From Strategy to Business Models and onto Tactics , 2010 .

[57]  Mary Tripsas,et al.  1 Technology and Industry Evolution , 2008 .

[58]  C. Hill,et al.  The Performance of Incumbent firms in the Face of Radical Technological Innovation , 2003 .

[59]  Vincent Mangematin,et al.  Do Science and Money Go Together? The Case of the French Biotech Industry , 2008 .

[60]  A. Strauss,et al.  The discovery of grounded theory: strategies for qualitative research aldine de gruyter , 1968 .

[61]  G. Hodgkinson,et al.  Cognitive Inertia in a Turbulent Market: The Case of UK Residential Estate Agents , 1997 .

[62]  Kathleen M. Eisenhardt,et al.  Theory Building From Cases: Opportunities And Challenges , 2007 .

[63]  Louis Galambos,et al.  Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.

[64]  James M. Utterback,et al.  A dynamic model of process and product innovation , 1975 .

[65]  Jaideep Anand,et al.  Alliance Activity as a Dynamic Capability in the Face of a Discontinuous Technological Change , 2010, Organ. Sci..

[66]  S. Hill,et al.  Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries , 2004 .

[67]  F. Rothaermel Complementary Assets, Strategic Alliances, and the Incumbent's Advantage: An Empirical Study of Industry and Firm Effects in the Biopharmaceutical Industry , 2001 .

[68]  D. Teece Business Models, Business Strategy and Innovation , 2010 .

[69]  Paul Nightingale,et al.  The myth of the biotech revolution: An assessment of technological, clinical and organisational change , 2007 .

[70]  T. Kuhn,et al.  The Structure of Scientific Revolutions. , 1964 .

[71]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[72]  M. V. Geenhuizen,et al.  Does a clustered location matter for high-technology companies' performance? The case of biotechnology in the Netherlands , 2007 .

[73]  R. D. De George Intellectual property and pharmaceutical drugs: an ethical analysis. , 2005, Business ethics quarterly : the journal of the Society for Business Ethics.

[74]  Walter W. Powell,et al.  Biotechnology: Its origins, organization, and outputs , 2007 .

[75]  Harold A. Linstone,et al.  Three eras of technology foresight , 2011 .

[76]  C. Gilbert Unbundling the Structure of Inertia: Resource Versus Routine Rigidity , 2005 .

[77]  Transforming the critique of Big Pharma , 2011 .

[78]  Anna Nosella,et al.  Characteristics of the Italian biotechnology industry and new business models: the initial results of an empirical study , 2005 .

[79]  V. Mangematin,et al.  Orchestrating networks in the biopharmaceutical industry: small hub firms can do it , 2010 .

[80]  K. Eisenhardt Building theories from case study research , 1989, STUDI ORGANIZZATIVI.

[81]  A. Pettigrew Longitudinal Field Research on Change: Theory and Practice , 1990 .

[82]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[83]  S. Walsh,et al.  Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry , 2011 .

[84]  Ron Bradfield,et al.  Four scenarios for the future of the pharmaceutical industry , 2009, Technol. Anal. Strateg. Manag..

[85]  Matthew B. Miles,et al.  Qualitative Data Analysis: An Expanded Sourcebook , 1994 .

[86]  Frank T. Rothaermel,et al.  Technological discontinuities and interfirm cooperation: what determines a startup's attractiveness as alliance partner? , 2002, IEEE Trans. Engineering Management.

[87]  N. Phillips,et al.  The Birth of the 'Kodak Moment': Institutional Entrepreneurship and the Adoption of New Technologies , 2005 .

[88]  A. McGahan,et al.  Business-Model Innovation: General Purpose Technologies and their Implications for Industry Structure , 2010 .

[89]  F. Rothaermel Technological Discontinuities and the Nature of Competition , 2000 .

[90]  F. Rothaermel Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .

[91]  B. S. Piachaud,et al.  Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience , 2002 .

[92]  Anil K. Gupta,et al.  Strategic innovation: a conceptual road map , 2001 .

[93]  Arvind Parkhe,et al.  Orchestrating Innovation Networks , 2006 .

[94]  G. Pisano Can science be a business? Lessons from biotech. , 2006, Harvard business review.

[95]  S. Walsh,et al.  IAMOT and Education: Defining a Technology and Innovation Management (TIM) Body-of-Knowledge (BoK) for graduate education (TIM BoK) , 2010 .

[96]  D. Teece Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[97]  Friedrich Grosse-Dunker,et al.  Sustainbility Innovation Cube , 2009 .